Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 155

1.

Molecular phenotypes in triple negative breast cancer from African American patients suggest targets for therapy.

Lindner R, Sullivan C, Offor O, Lezon-Geyda K, Halligan K, Fischbach N, Shah M, Bossuyt V, Schulz V, Tuck DP, Harris LN.

PLoS One. 2013 Nov 18;8(11):e71915. doi: 10.1371/journal.pone.0071915. eCollection 2013.

PMID:
24260093
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Triple-negative breast cancer: disease entity or title of convenience?

Carey L, Winer E, Viale G, Cameron D, Gianni L.

Nat Rev Clin Oncol. 2010 Dec;7(12):683-92. doi: 10.1038/nrclinonc.2010.154. Epub 2010 Sep 28. Review.

PMID:
20877296
[PubMed - indexed for MEDLINE]
3.

Differences in the tumor microenvironment between African-American and European-American breast cancer patients.

Martin DN, Boersma BJ, Yi M, Reimers M, Howe TM, Yfantis HG, Tsai YC, Williams EH, Lee DH, Stephens RM, Weissman AM, Ambs S.

PLoS One. 2009;4(2):e4531. doi: 10.1371/journal.pone.0004531. Epub 2009 Feb 19.

PMID:
19225562
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Triple negative breast tumors in African-American and Hispanic/Latina women are high in CD44+, low in CD24+, and have loss of PTEN.

Wu Y, Sarkissyan M, Elshimali Y, Vadgama JV.

PLoS One. 2013 Oct 22;8(10):e78259. doi: 10.1371/journal.pone.0078259. eCollection 2013.

PMID:
24167614
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Differentially expressed transcripts and dysregulated signaling pathways and networks in African American breast cancer.

Stewart PA, Luks J, Roycik MD, Sang QX, Zhang J.

PLoS One. 2013 Dec 4;8(12):e82460. doi: 10.1371/journal.pone.0082460. eCollection 2013.

PMID:
24324792
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Racial differences in outcomes of triple-negative breast cancer.

Pacheco JM, Gao F, Bumb C, Ellis MJ, Ma CX.

Breast Cancer Res Treat. 2013 Feb;138(1):281-9. doi: 10.1007/s10549-012-2397-6. Epub 2013 Feb 12.

PMID:
23400579
[PubMed - indexed for MEDLINE]
7.

Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer.

Cheng Q, Chang JT, Geradts J, Neckers LM, Haystead T, Spector NL, Lyerly HK.

Breast Cancer Res. 2012 Apr 17;14(2):R62.

PMID:
22510516
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer.

Cabezón T, Gromova I, Gromov P, Serizawa R, Timmermans Wielenga V, Kroman N, Celis JE, Moreira JM.

Mol Cell Proteomics. 2013 Feb;12(2):381-94. doi: 10.1074/mcp.M112.019786. Epub 2012 Nov 20.

PMID:
23172894
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Vimentin as a poor prognostic factor for triple-negative breast cancer.

Yamashita N, Tokunaga E, Kitao H, Hisamatsu Y, Taketani K, Akiyoshi S, Okada S, Aishima S, Morita M, Maehara Y.

J Cancer Res Clin Oncol. 2013 May;139(5):739-46. doi: 10.1007/s00432-013-1376-6. Epub 2013 Jan 26.

PMID:
23354842
[PubMed - indexed for MEDLINE]
10.

Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.

Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA.

J Surg Res. 2007 Nov;143(1):109-18.

PMID:
17950079
[PubMed - indexed for MEDLINE]
11.

Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer.

Neumeister VM, Sullivan CA, Lindner R, Lezon-Geyda K, Li J, Zavada J, Martel M, Glazer PM, Tuck DP, Rimm DL, Harris L.

Breast Cancer Res Treat. 2012 Nov;136(1):67-75. doi: 10.1007/s10549-012-2232-0. Epub 2012 Sep 14.

PMID:
22976806
[PubMed - indexed for MEDLINE]
12.

Expression of melatonin receptors in triple negative breast cancer (TNBC) in African American and Caucasian women: relation to survival.

Oprea-Ilies G, Haus E, Sackett-Lundeen L, Liu Y, McLendon L, Busch R, Adams A, Cohen C.

Breast Cancer Res Treat. 2013 Feb;137(3):677-87. doi: 10.1007/s10549-012-2371-3. Epub 2012 Dec 19.

PMID:
23250547
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Insulin-like growth factors I and II receptors in the breast cancer survival disparity among African-American women.

Kalla Singh S, Tan QW, Brito C, De León M, De León D.

Growth Horm IGF Res. 2010 Jun;20(3):245-54. doi: 10.1016/j.ghir.2010.03.001. Epub 2010 Mar 27.

PMID:
20347606
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Differences in autophagy-related activity by molecular subtype in triple-negative breast cancer.

Kim S, Jung WH, Koo JS.

Tumour Biol. 2012 Oct;33(5):1681-94. doi: 10.1007/s13277-012-0424-1. Epub 2012 May 27.

PMID:
22638807
[PubMed - indexed for MEDLINE]
15.

Clinical significance of p53 and bcl-2 protein coexpression phenotypes in molecular breast cancer subtypes of pre-menopausal and post-menopausal African-American women.

Ihemelandu CU, Dewitty RL Jr, Leffall LD Jr, Suryanarayana SM, Frederick WA.

Am Surg. 2009 Sep;75(9):776-84; discussion 784.

PMID:
19774948
[PubMed - indexed for MEDLINE]
16.

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA.

J Clin Invest. 2011 Jul;121(7):2750-67. doi: 10.1172/JCI45014.

PMID:
21633166
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

A collaborative study of the etiology of breast cancer subtypes in African American women: the AMBER consortium.

Palmer JR, Ambrosone CB, Olshan AF.

Cancer Causes Control. 2014 Mar;25(3):309-19. doi: 10.1007/s10552-013-0332-8. Epub 2013 Dec 17.

PMID:
24343304
[PubMed - indexed for MEDLINE]
18.

[The morphology of triple negative breast cancer].

Karseladze DA, Poddubnaia IV, Karseladze AI.

Arkh Patol. 2010 Mar-Apr;72(2):8-12. Russian.

PMID:
20698308
[PubMed - indexed for MEDLINE]
19.

Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor status.

Cunningham JE, Montero AJ, Garrett-Mayer E, Berkel HJ, Ely B.

Cancer Causes Control. 2010 Mar;21(3):399-409. doi: 10.1007/s10552-009-9472-2. Epub 2009 Dec 19.

PMID:
20024610
[PubMed - indexed for MEDLINE]
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk